Literature DB >> 3018414

Abnormalities in the central cholinergic transmitter system of the genetically epilepsy-prone rat.

H E Laird, M Hadjiconstantinou, N H Neff.   

Abstract

Seizure-experienced Genetically Epilepsy-prone Rats (GEPRs) have increased acetylcholine content and choline acetyltransferase activity in the thalamus and striatum. These cholinergic differences are accompanied by a slight but statistically significant reduction in acetylcholinesterase activity in the midbrain. In addition, no abnormalities were found in the numbers of specific 3H-QNB binding sites in the striatum, hippocampus, inferior colliculi or cortex. Other work has shown no difference in muscarinic receptor function as measured by carbachol-stimulated inositol-1-phosphate formation. These data suggest a possible presynaptic defect in the striatal and thalamic cholinergic system which may play some role in the seizure-prone state of the GEPR. However, caution must be used in interpreting these cholinergic derangements since more recent findings show no differences in thalamic acetylcholine content in seizure-naive GEPRs. Thus, the original cholinergic abnormalities detected in the seizure-experienced GEPR may be an enduring response to seizure activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018414     DOI: 10.1016/0024-3205(86)90456-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Sequential 123I-iododexetimide scans in temporal lobe epilepsy: comparison with neuroimaging scans (MR imaging and 18F-FDG PET imaging).

Authors:  Armin Mohamed; Stefan Eberl; Michael J Fulham; Michael Kassiou; Aysha Zaman; David Henderson; Scott Beveridge; Chris Constable; Sing Kai Lo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-23       Impact factor: 9.236

Review 2.  Rhythm and blues: animal models of epilepsy and depression comorbidity.

Authors:  S Alisha Epps; David Weinshenker
Journal:  Biochem Pharmacol       Date:  2012-08-23       Impact factor: 5.858

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.